Abstract: The present invention is to provide an inhibitor that inhibits differentiation of T cells into Th1 cells. The inhibitor that inhibits differentiation of T cells into Th1 cells contains, as an active ingredient, pitavastatin or a salt thereof.
Type:
Grant
Filed:
July 18, 2008
Date of Patent:
March 12, 2013
Assignees:
Kowa Co., Ltd., National University Corporation Nagoya University
Abstract: The present invention relates to a solid pharmaceutical composition for oral administration, containing the following components (A) and (B): 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (compound a) or an acid addition salt thereof, and (B) citric acid. An improvement is achieved in the dissolubility of the compound a, which is useful as a therapeutic agent for hypercholesterolemia, arteriosclerosis, and the like.
Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.
Type:
Grant
Filed:
August 8, 2011
Date of Patent:
January 29, 2013
Assignees:
Kowa Co., Ltd., Tokyo University of Science Educational Foundation Administrative Organization
Inventors:
Toshio Inagi, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi
Abstract: Provided is a film preparation in which an unpleasant taste derived from a medicament is masked. The film preparation includes coating layers containing no terpene formed on both sides of a medicament-containing layer containing a medicament having an unpleasant taste and a terpene.
Abstract: The present invention relates to a solid pharmaceutical composition for oral administration, containing the following components (A) and (B): (A) 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide (compound a) or an acid addition salt thereof, and (B) organic acid selected from the group consisting of tartaric acid, malic acid, ascorbic acid and benzoic acid. An improvement is achieved in the dissolubility of the compound a, which is useful as a therapeutic agent for hypercholesterolemia, arteriosclerosis, and the like.
Abstract: The present invention provides a stable complex microbial system, which simultaneously decomposes a plurality of organic contaminants even under a polluted environment with these contaminants and permits more effective decomposition of persistent organic contaminants such as PCNB and simazine. A support for holding a complexed accumulation of degrading bacteria, which contains a porous material provided as a support on which a degrading bacterium A capable of degrading at least one organic contaminant and a degrading bacterium B capable of degrading another organic contaminant are accumulated, is produced. The degrading bacterium A may be a PCNB-degrading bacterium, particularly a degrading bacterium containing a degrading bacterium having part or all of mycological characteristics of Nocardioides sp. PD653 and the degrading bacterium B may be a degrading bacterium containing a degrading bacterium having part or all of mycological characteristics of ?-Proteobacteria CDB21.
Type:
Grant
Filed:
September 16, 2009
Date of Patent:
October 9, 2012
Assignees:
National Institute for Agro-Environmental Sciences Independent Administrative Institute, Kowa Co., Ltd.
Abstract: A peritoneal dialysate containing adenosine triphosphate or a salt thereof, and a peritoneal dialysis method using the dialysate. The peritoneal dialysate is safe and causes less peritoneal injuries even when employed in peritoneal dialysis over a long period of time.
Abstract: An FGF21 production promoting agent containing, as an active ingredient, a compound represented by the following formula (1): wherein each of R1 and R2, which may be identical to or different from each other, represents, for example, a hydrogen atom; each of R3a, R3b, R4a, and R4b, which may be identical to or different from one another, represents, for example, a hydrogen atom or a halogen atom, or R3a and R3b or R4a and R4b may bond together to form an alkylenedioxy group; X represents an oxygen atom, a sulfur atom, or N—R5 (R5 represents, for example, a hydrogen atom or a C1-4 alkyl group); Y represents, for example, an oxygen atom, an S(O)l group (l is a number of from 0 to 2), or a carbonyl group; Z represents CH or N; n is a number of from 1 to 6; and m is a number from 2 to 6, a salt of the compound, or a solvate of the compound or the salt.
Abstract: There is Provided an Agent for Prevention of glaucoma or an agent for prevention or treatment of ocular hypertension, with a potent ocular hypotensive effect and prolonged duration thereof. An agent for prevention or treatment of glaucoma comprising a Rho kinase inhibitor and a carbonic anhydrase inhibitor in combination.
Abstract: The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.
Type:
Application
Filed:
December 22, 2011
Publication date:
April 19, 2012
Applicants:
Nissan Chemical Industries Ltd., Kowa Co., Ltd.
Abstract: To provide a lead concentration determination reagent which realizes accurate, high-sensitivity, and simple-manner determination of the lead ion concentration (also referred to simply as “lead concentration”) of a sample solution in the presence of calcium ions, and a lead concentration determination method employing the reagent. The lead concentration determination reagent contains (A) a water-soluble porphyrin derivative or a salt thereof, (B) at least one member selected from among polyacrylamide, polyvinyl alcohol, and polyethylene glycol, and (C) a calcium-ion-supplying compound.
Abstract: The present invention is directed to a triglyceride-lowering agent, exhibiting excellent triglyceride-lowering effect and a hyperinsulinemia-ameliorating agent. The triglyceride-lowering agent and hyperinsulinemia-ameliorating agent are characterized by containing a pitavastatin compound, and amlodipine or a salt thereof.
Type:
Grant
Filed:
March 28, 2007
Date of Patent:
February 28, 2012
Assignees:
Kowa Co., Ltd., Nissan Chemical Industries, Ltd.
Abstract: A composition containing an extremely poorly water-soluble drug and obtained by treating, with a supercritical fluid or subcritical fluid of carbon dioxide, a mixture comprising a porous silica material and the extremely poorly water-soluble drug; and its production process. The porous silica material has an average pore diameter in a range of from 1 to 20 nm, pores having diameters within ±40% of the average pore size account for at least 60% of a total pore volume of the porous silica material, and in X-ray diffractometry, the porous silica material has at least one peak at a position of diffraction angle (2?) corresponding to a d value of at least 1 nm. The composition according to the present invention, which contains the extremely poorly water-soluble drug, is excellent in the dissolution of the extremely poorly water-soluble drug.
Type:
Grant
Filed:
April 28, 2004
Date of Patent:
January 31, 2012
Assignees:
Kowa Co., Ltd., Kabushiki Kaisha Toyota Chuo Kenkyusho
Abstract: A composition containing a very low water-soluble drug, which composition is produced by treating, with a supercritical or subcritical carbon dioxide fluid, a mixture containing a very low water-soluble drug and a porous material (exclusive of a porous silica material characterized in that the material has an average pore diameter of 1 to 20 nm, the total pore volume of the material that have a diameter falling within a range of ±40% of the average pore diameter account for 60% or more the volume of all the pores of the material, and, when subjected to X-ray diffractometry, the material exhibits one or more peaks at a diffraction angle (2?) corresponding to d of 1 nm or more); and a method for producing the composition. The very-low-water-soluble-drug-containing composition of the present invention ensures improved dissolution of the very low water-soluble drug.
Abstract: An external preparation containing the following components (A), (B), and (C): (A) a non-steroidal analgesic/anti-inflammatory agent, (B) a polyhydric alcohol, and (C) a polyoxyalkylene alkyl ether and/or a polyoxyalkylene alkenyl ether. The external preparation of the present invention has improved the drug efficacy of a non-steroidal analgesic/anti-inflammatory agent, and can be effective at a low concentration. The external preparation of the present invention also has excellent appearance.
Abstract: An external preparation containing the following components (A), (B), (C), and (D): (A) a non-steroidal analgesic/anti-inflammatory agent, (B) a terpene and/or an essential oil containing a terpene, (C) a higher alcohol, and (D) a polyoxyalkylene alkyl ether and/or a polyoxyalkylene alkenyl ether. The external preparation of the present invention has improved skin permeation, and can thus be effective at a low concentration, and also has excellent appearance.
Abstract: An external preparation containing the following components (A) and (B): (A) a non-steroidal analgesic/anti-inflammatory agent, and (B) an organic amine. The external preparation of the present invention has improved skin permeation and excellent stability of a non-steroidal analgesic/anti-inflammatory agent in the external preparation. The external preparation of the present invention also has excellent appearance.
Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.
Type:
Application
Filed:
August 8, 2011
Publication date:
December 1, 2011
Applicants:
Tokyo Univ. of Sci. Edu. Fdn. Admin. Org., Kowa Co., Ltd.
Inventors:
Toshio INAGI, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi
Abstract: A screening method for a preventive or therapeutic agent for an autoimmune disease and/or for an apoptosis inhibitor, comprising determining retinoblastoma associated protein (RBAp48) production suppressing effect or RBAp48 production inhibitory effect of a sample.
Abstract: The present invention is to provide means to treat breast cancer and/or mastitis by topically administering a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent and allowing them efficiently to arrive into the mammary gland. The present invention provides an iontophoretic preparation for treating breast cancer and/or mastitis which contains a non-steroidal antiinflammatory analgetic agent and/or an anticancer agent as an active ingredient and has a donor to be applied on a nipple part for topical administration of the active ingredient from the nipple part to the mammary gland by application of electric potential.
Type:
Grant
Filed:
October 11, 2006
Date of Patent:
October 11, 2011
Assignees:
Kowa Co., Ltd., Tokyo University of Science Educational Foundation Administrative Organization
Inventors:
Toshio Inagi, Makoto Kanebako, Hiroshi Terada, Kimiko Makino, Masakazu Toi